Phase 4 Adenosine Pre-Medication in Primary PCI Randomized Control Trial
ClinicalTrials.gov Studies
Summary
NIH registered a Phase 4 clinical trial (NCT07536802) evaluating adenosine pre-medication versus standard care in primary percutaneous coronary intervention for ST-segment elevation myocardial infarction patients. The randomized controlled trial aims to assess impact on slow flow/no-reflow phenomenon incidence. The trial is registered on ClinicalTrials.gov.
What changed
NIH registered a new Phase 4 clinical trial on ClinicalTrials.gov examining adenosine pre-medication in primary PCI for STEMI patients. The randomized controlled trial will compare adenosine pre-medication against standard care to evaluate impact on slow flow/no-reflow phenomenon.
Healthcare providers and clinical investigators conducting cardiac research may find this registry entry relevant for identifying ongoing studies in this therapeutic area. The trial represents standard clinical research activity registered with NIH and does not impose compliance obligations on healthcare entities.
Archived snapshot
Apr 18, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention: A Randomized Control Trial
Phase 4 NCT07536802 Kind: PHASE4 Apr 17, 2026
Abstract
Primary objective of the study is to evaluate the impact of adenosine pre-medication on incidence of slow flow/no-reflow after primary percutaneous coronary intervention.
Conditions: ST-Segment Elevation Myocardial Infarction (STEMI), No-Reflow Phenomenon, Coronary Slow Flow, Acute Myocardial Infarction
Interventions: Adenosine pre-medication, Standard care
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.